The Brain Disease Modalities And Software Market Size is valued at 13.51 Billion in 2022 and is predicted to reach 21.12 Billion by the year 2031 at a 5.23 % CAGR during the forecast period for 2023-2031.
Brain disease modalities are medical imaging techniques that are used to diagnose and monitor brain diseases. Brain disease software is used to analyze the images that are produced by brain disease modalities. Brain disease software can be used to identify and measure abnormalities in the brain, to track changes over time, and to plan treatment.
Conventional imaging methods for diagnosing brain disorders include MRI, CT scans, PET, and a combination of PET and MRI or CT features. While a magnetic field and radio waves are used in magnetic resonance imaging (MRI), a computerised tomography scan (CT) produces multi-angular cross-sectional X-ray images. These imaging methods are utilised to monitor vital processes such as brain oxygenation capacity, blood pressure, traumatic cranial injury, strokes, tumours, and neural activity.
The combined advancements in brain disease modalities and software have transformed the neurological diagnosis and treatment landscape. Through improved imaging technologies and sophisticated software tools, medical professionals can identify brain diseases at earlier stages, understand their underlying mechanisms better, and tailor treatment plans for individual patients. Continued research and integration of emerging technologies promise to drive further progress in neurology and offer new hope for patients with brain disorders.
The medical field's AI advancements, rising demand for safe medical imaging devices during surgeries, and increasing prevalence of neurological disorders are significant market drivers. However, the lack of affordability of non-invasive imaging devices hampers market growth in developing economies like Latin America, the Middle East, and Africa. Consequently, the low- and middle-income populations rely on alternative preliminary methods like blood biomarker tests and cognitive scoring tests for neurological disorder diagnosis. Globally, the shortage of Helium gas adversely affects medical imaging as it is essential for cooling down imaging devices after testing, directly impacting their functionality. Despite a decline in the demand for neuroimaging services, there has been a compensatory need for respiratory imaging techniques and COVID-19 treatment tests.
Key Developments:
- In Mar 2021, DiA Imaging Analysis declared its collaboration with Royal Phillips to offer hiqh-quality ultrasound imaging with artificial intelligence (AI)-based image quantification. AI-based solutions are applied for a range of applications ranging from image detection to diagnosis and decision support, image acquisition, reporting and communication, triage, image analysis, and predictive analysis and risk assessment, among others.
- In Jan 2022, New MRI technology is developed by Siemens company in alliance with researchers at The Ohio State University College, will magnify imaging access for patients with implanted medical devices, claustrophobia and severe obesity
Market Segmentation:
Brain disease modalities and software market are segmented into three main categories: Patients, Products and End-Users. First Patient Type is again subcategories in Adults, Paediatrics and Infants. Secondly, End-Users are subdivided into Hospitals and Clinics, Ambulatory Surgery Centers, Diagnostic Imaging Centers. The last and third segment is by Products in that Brain Imaging Modalities and Brain Analysis Software are two subdivisions. There are five types of brain imaging modalities PET devices, CT devices, MRI devices, PET-CT, PET-MRI.
Almost all the regions are covered under the global brain disease modalities and software market consisting North America, Europe, Asia-Pacific and rest of the world. Besides North America and Europe being the largest market, other developing countries expect strong growth shortly.
Competitive Landscape:
Some of The Key Players in The Brain disease modalities and software Market:
- Quantib
- Brainomix
- AI
- General Electric Company
- Imaging Biometrics, LLC
- United Imaging Healthcare Co. Ltd.
- Siemens
- Healthineers AG
- Koninklijke Philips N.V.
- Canon Inc.
- Vuno Co. Ltd.
- Aspect Imaging
- IXICO
- QMENTA
- ai
- I. Analysis Inc.
- Fujifilm Holdings Corporation
- Other Prominent Players.
The Brain disease modalities and software Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 12.51 Billion |
|
Revenue Forecast In 2031 |
USD 21.12 Billion |
|
Growth Rate CAGR |
CAGR of 5.23 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Type of Patients, By End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
United Imaging Healthcare, Koninklijke Philips N.V., General Electric Company, Canon Inc., Siemens Healthineers AG, Vuno Co., Ltd., Fujifilm Holdings Corporation, Aspect Imaging, IXICO, QMENTA, Cortechs.ai, Quantib, Brainomix, Qure.AI, Imaging Biometrics and A.I., and Analysis, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
